Stock Analysis on Net

Moderna Inc. (NASDAQ:MRNA)

This company has been moved to the archive! The financial data has not been updated since November 7, 2024.

Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data

Moderna Inc., consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

US$ in millions

Microsoft Excel
Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Accounts payable 373 279 183 520 494 310 389 487 330 181 199 302 87 77 8 18 21 19 11 7 12 30 39
Accrued liabilities 1,376 1,333 1,396 1,798 2,224 1,490 1,613 2,101 1,856 1,780 1,608 1,472 1,076 848 753 470 209 89 55 68 60 45 42
Deferred revenue 379 702 559 568 1,372 1,040 1,219 2,038 4,002 4,093 5,599 6,253 7,977 7,302 7,531 3,867 1,235 45 59 63 70 83 74
Income taxes payable 4 7 52 63 56 47 66 48 66 349 1,592 876 565
Other current liabilities 69 42 190 66 239 236 212 249 553 409 240 225 252 613 149 34 10 8 10 5 6 4 5
Current liabilities 2,201 2,363 2,380 3,015 4,385 3,123 3,499 4,923 6,807 6,812 9,238 9,128 9,957 8,840 8,441 4,389 1,474 162 135 143 148 162 159
Deferred revenue, non-current 95 95 58 83 166 692 673 673 175 405 464 615 498 175 179 177 208 208 143 139 143 140 157
Operating lease liabilities, non-current 679 668 637 643 697 104 96 92 79 87 95 106 105 105 96 97 99 100 109 94
Financing lease liabilities, non-current 625 576 575 575 575 843 831 912 922 641 646 599 238 328 138 110 109 68 39 39
Deferred lease obligation, non-current 14 11 11
Lease financing obligation 34 34 33
Other non-current liabilities 276 266 262 256 172 173 163 135 81 113 91 76 1 1 2 2 2 1 1
Non-current liabilities 1,675 1,605 1,532 1,557 1,610 1,812 1,763 1,812 1,257 1,246 1,296 1,396 842 609 415 387 418 377 292 271 191 185 201
Total liabilities 3,876 3,968 3,912 4,572 5,995 4,935 5,262 6,735 8,064 8,058 10,534 10,524 10,799 9,449 8,856 4,775 1,891 539 427 415 339 347 360
Preferred stock, par value $0.0001; no shares issued or outstanding
Common stock, par value $0.0001
Additional paid-in capital 751 631 487 371 277 193 731 1,173 1,488 2,413 3,644 4,211 5,003 4,931 4,860 4,802 4,726 4,676 3,268 2,669 2,618 2,582 2,557
Accumulated other comprehensive income (loss) 11 (71) (101) (123) (211) (263) (267) (370) (351) (240) (184) (24) 31 16 1 3 5 8 (6) 2 3 3 1
Retained earnings (accumulated deficit) 11,165 11,152 12,431 13,606 13,389 17,019 18,399 18,320 16,855 15,812 13,615 9,958 5,090 1,757 (1,023) (2,244) (1,971) (1,737) (1,621) (1,496) (1,370) (1,246) (1,111)
Stockholders’ equity 11,927 11,712 12,817 13,854 13,455 16,949 18,863 19,123 17,992 17,985 17,075 14,145 10,124 6,704 3,838 2,561 2,760 2,947 1,641 1,175 1,252 1,339 1,446
Total liabilities and stockholders’ equity 15,803 15,680 16,729 18,426 19,450 21,884 24,125 25,858 26,056 26,043 27,609 24,669 20,923 16,153 12,694 7,337 4,651 3,486 2,068 1,589 1,591 1,685 1,806

Based on: 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Moderna Inc. current liabilities decreased from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024.
Non-current liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Moderna Inc. non-current liabilities increased from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Moderna Inc. total liabilities increased from Q1 2024 to Q2 2024 but then decreased significantly from Q2 2024 to Q3 2024.
Stockholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Moderna Inc. stockholders’ equity decreased from Q1 2024 to Q2 2024 but then slightly increased from Q2 2024 to Q3 2024.